LAUREN KYZAR: Open Payments
NPI 1215552021 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$350 in 17 payments from 11 companies in 2025. Trend: 2023 $5,633 · 2024 $4,979 · 2025 $350
Food & beverage: $350
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $74 |
| CSL Behring | 2 | $69 |
| Neurocrine BioSciences, Inc. | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| Alexion Pharmaceuticals, Inc. | 1 | $29 |
| Lilly USA, LLC | 1 | $20 |
| ACADIA Pharmaceuticals Inc | 1 | $19 |
| ARGENX US, INC. | 1 | $18 |
| Amgen Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
Products named: Hizentra, INGREZZA, VRAYLAR, ULTOMIRIS, UBRELVY, KISUNLA, NUPLAZID, Sunosi.
Industry payments across AL — which companies pay providers there.
